Suvi Sorsa
PhD, VP of Clinical Affairs
VP of Clinical Affairs, Suvi Sorsa, has extensive experience in cancer biology and gene therapy, especially with oncolytic viruses. Suvi has a PhD from the Cancer Gene Therapy Group (Helsinki, Finland), has worked at Ark Therapeutics, and has co-authored dozens of scientific papers with an emphasis on tumor immunotherapy. Suvi is responsible for clinical research, protocols and clinical sample analysis. Suvi has been closely involved in the entire development of TILT´s oncolytic viruses, from preclinical studies, through regulatory review, and eventually in clinical development .
